AbbVie Stock - New Phase 3 venetoclax data presented at EHA

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 17:27 CET. Details in the imprint.

AbbVie Inc. (US00287Y1091) has highlighted new Phase 3 data for a fixed-duration venetoclax-based combination in blood cancer at the European Hematology Association 2026 meeting. The update was published on June 12, 2026, according to an AbbVie news center release.

What AbbVie reported at EHA

AbbVie used the European Hematology Association 2026 congress in Madrid to showcase new Phase 3 results for a fixed-duration venetoclax-based regimen in hematologic malignancies, underlining its ongoing push in oncology.

According to the company’s news center, the data concern a combination including venetoclax, developed with partner Roche, aimed at delivering time-limited treatment with durable responses in certain blood cancers.

Operational context on a Wednesday

From an operational perspective, the new data slot into AbbVie’s wider effort to refresh its portfolio after Humira’s US exclusivity loss, with oncology and immunology targeted as long-term pillars.

The company continues to invest heavily in late-stage programs, using congress milestones such as EHA to signal clinical progress to physicians, regulators and investors, and to support future regulatory submissions.

How the company makes money

AbbVie generates most of its revenue from branded prescription drugs in immunology, oncology, neuroscience, aesthetics and eye care, including flagship products such as Skyrizi for psoriasis and Rinvoq for inflammatory diseases.

Where the stock trades today

AbbVie shares (US00287Y1091) trade on the New York Stock Exchange at $221.59 as of 06/17/2026, 17:00 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.